384 related articles for article (PubMed ID: 23588311)
1. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.
Zamek-Gliszczynski MJ; Lee CA; Poirier A; Bentz J; Chu X; Ellens H; Ishikawa T; Jamei M; Kalvass JC; Nagar S; Pang KS; Korzekwa K; Swaan PW; Taub ME; Zhao P; Galetin A;
Clin Pharmacol Ther; 2013 Jul; 94(1):64-79. PubMed ID: 23588311
[TBL] [Abstract][Full Text] [Related]
2. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance.
Liang X; Lai Y
Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):869-886. PubMed ID: 33793347
[No Abstract] [Full Text] [Related]
5. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
Chu X; Korzekwa K; Elsby R; Fenner K; Galetin A; Lai Y; Matsson P; Moss A; Nagar S; Rosania GR; Bai JP; Polli JW; Sugiyama Y; Brouwer KL;
Clin Pharmacol Ther; 2013 Jul; 94(1):126-41. PubMed ID: 23588320
[TBL] [Abstract][Full Text] [Related]
6. Transporter biology in drug approval: regulatory aspects.
Maeda K; Sugiyama Y
Mol Aspects Med; 2013; 34(2-3):711-8. PubMed ID: 23506904
[TBL] [Abstract][Full Text] [Related]
7. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
8. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
Guo Y; Chu X; Parrott NJ; Brouwer KLR; Hsu V; Nagar S; Matsson P; Sharma P; Snoeys J; Sugiyama Y; Tatosian D; Unadkat JD; Huang SM; Galetin A;
Clin Pharmacol Ther; 2018 Nov; 104(5):865-889. PubMed ID: 30059145
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
Soars MG; Webborn PJ; Riley RJ
Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
[TBL] [Abstract][Full Text] [Related]
11. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.
Zamek-Gliszczynski MJ; Taub ME; Chothe PP; Chu X; Giacomini KM; Kim RB; Ray AS; Stocker SL; Unadkat JD; Wittwer MB; Xia C; Yee SW; Zhang L; Zhang Y;
Clin Pharmacol Ther; 2018 Nov; 104(5):890-899. PubMed ID: 30091177
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.
Shou M
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):66-77. PubMed ID: 15679174
[TBL] [Abstract][Full Text] [Related]
13. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
Langer O
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
Okudaira N
J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
[TBL] [Abstract][Full Text] [Related]
15. Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model.
Patilea-Vrana G; Unadkat JD
Clin Pharmacol Ther; 2016 Nov; 100(5):413-418. PubMed ID: 27448198
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions.
Maeda K
Drug Metab Pharmacokinet; 2020 Feb; 35(1):76-88. PubMed ID: 31948854
[TBL] [Abstract][Full Text] [Related]
17. EUFEPS conference on drug transporters at Copenhagen: integrative approaches in ADME research.
Meijer DK; Lennernäs H
Eur J Pharm Sci; 2005 Sep; 26(1):130-43. PubMed ID: 16161216
[No Abstract] [Full Text] [Related]
18. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
19. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.
Wulkersdorfer B; Wanek T; Bauer M; Zeitlinger M; Müller M; Langer O
Clin Pharmacol Ther; 2014 Aug; 96(2):206-13. PubMed ID: 24682030
[TBL] [Abstract][Full Text] [Related]
20. Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling.
Galetin A
Methods Mol Biol; 2014; 1113():255-88. PubMed ID: 24523117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
